The global blood culture tests market size was valued at USD 4.54 billion in 2021. It is expected to reach USD 10.30 billion by 2030, growing at a CAGR of 10.2% during the forecast period (2022–2030).
A blood culture can determine the presence of microorganisms in the blood, including bacteria, yeast, and other microorganisms. This study focuses solely on the products, not the accompanying services. The significant factors that contribute to the expansion of the global market for blood culture tests are:
In addition, the government's implementation of stringent regulations for the development and manufacturing of blood culture tests product is a driving force behind the market expansion. A further factor contributing to the expansion of the market is the growing consciousness regarding the role of healthcare in preventing infectious diseases.
Early identification of blood infections is essential to prevent future consequences because the majority of blood infections are brought on by bacteria entering the bloodstream through the skin, lungs, urine, or gastrointestinal system. Blood infections can be potentially fatal when the body's immune system reacts to an infection by damaging its tissues. According to data from 2019, 6 million people die every year from bloodstream illnesses, affecting 30 million individuals. The rise in bacterial illnesses is primarily caused by changing lifestyles and rising pollution. Blood culture tests are becoming more widely used to screen for potential problems due to the increasing number of government programs in various nations to assist in early diagnosis. For instance, the Get Ahead of Sepsis campaign was developed by the Centers for Disease Control and Prevention as a public health effort to safeguard Americans against sepsis. The project focuses on preventing infections that cause sepsis and an early medical diagnosis and treatment of the condition. Blood culture tests can help doctors identify infections early on since untreated blood infections can be severe and result in organ failure and even death. Complete body tests have also become more popular due to rising healthcare awareness among the populace, which is anticipated to fuel market revenue development over the forecast period.
|Market Size||USD 10.30 billion|
|Fastest Growing Market||Europe|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
An alarming rise in the prevalence of infectious diseases such as blood and bloodstream infections has been observed, which acts as a critical driving force for the global market for blood culture tests. Infectious diseases are the leading cause of mortality and morbidity around the world. This includes conditions such as bloodstream infections and sepsis. In the countries of Eastern Africa, the incidence of infections in the bloodstream varies anywhere from 11% to 28%. According to a report published by the World Health Organization, it has been found that low- and middle-income countries account for 85 percent of all deaths caused by sepsis.
Blood culture tests make it possible to diagnose and treat these diseases relatively quickly, thereby preventing them from worsening or becoming life-threatening. Laboratory technicians and researchers used consumables like blood culture media, assays, kits and reagents, software and services, and other comparable products to detect microorganisms and, as a result, control the infection they cause. With the assistance of blood culture tests, it is possible to identify the infectious agent responsible for the blood infection. This paves the way for an accurate treatment prognosis and helps prevent any adverse effects that may be caused due to the severity of the disease.
A critical factor that drives the global market's expansion is the rise in investment in research and development activities conducted by various healthcare sectors to develop new products such as consumables, instruments, and software. The development of new products and services can be supported by investments in research and development (R&D), which also contribute to the company's expansion over the long term. Furthermore, the implementation of stringent regulations from the government for developing and manufacturing advanced diagnostic products, including blood culture test products, is expected to drive the market's growth during the forecast period. For example, the government engages in various programs to prevent and control infectious diseases, which drives the demand for blood culture tests.
The growth of the global blood culture tests market is the increase in the global geriatric population. This is because older adults are highly susceptible to developing immunosenescence, a condition in which the immune system does not function properly, and there is a decrease in the activity of the immune system. In addition, the prevalence of sepsis is significantly higher among the elderly population. This is since elderly patients tend to stay in the hospital for more extended periods and have a more significant number of comorbidities. The UN Population Division estimates that by 2050, there will be 1.5 billion people over 65 worldwide.
It is anticipated that the limited availability of blood culture tests will be a direct result of the high cost of automated blood culture instruments during the forecast period. As an illustration, the cost of polymerase chain reaction typically ranges between USD 10,000 and USD 15,000 on average. In addition, the price of a MALDI-TOF MS System ranges from 150,000 to 850,000 dollars. Academic research laboratories lack the funding to buy automated instruments due to the constrained budget for carrying out research. As a result, it is anticipated that this factor will prevent the market from growing during the time frame in question.
Blood samples are mixed with a unique substance called a culture as part of blood culture tests. To reduce collection errors, trained staff venipuncture peripheral blood culture specimens. All processes involve employing highly skilled employees, smart, sustainable capacity implementation, and automated technology to increase the possibility of identifying germs. However, over the anticipated period, it is anticipated that the Market's revenue growth will be hampered by a lack of appropriately qualified or skilled staff.
The laboratory diagnosis of bloodstream infections offers high accuracy and provides accurate responses intertwined with emerging technologies' ideas. These tests help distinguish between different organisms, such as Staphylococcus aureus. In addition, new blood culture identification assays (BCID) have 27 different targets, including Gram-negative, multiple Gram-positive, and other Candida targets. These assays detect Klebsiella pneumonia carbapenemase (KPC) and provide sample testing results in under an hour.
In addition, Luminex Corporation, a biotechnology company with applications in life science, was able to launch Verigene with the assistance of technological advancements. Verigene has thirty targets and results in six resistant genes for Gram-negative CTX-M-ESBL bacteria (CefiTaXime Extended Spectrum Beta-Lactamase).
The global blood culture tests market is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is anticipated to dominate the global blood culture tests market and is expected to reach USD 3.94 billion in 2030, growing at a CAGR of 8.3% during the forecast period. The presence of the target market, rising interest in the healthcare industry, and rising disposable income in the area are all anticipated to contribute to the market's expansion. The availability of highly developed healthcare infrastructure and cutting-edge diagnostic products in countries like the United Kingdom, France, and Switzerland contribute to an increase in the demand for blood culture tests to achieve a timely diagnosis. In addition, during the forecast period, the prevalence of bloodstream infections in Europe is anticipated to increase the demand for blood culture tests.
The availability of cutting-edge diagnostics products and highly developed healthcare infrastructure in European nations like Germany, the U.K., Switzerland, and France are expected to fuel market growth in Europe. Additionally, manufacturers' increasing R&D expenditures for creating new products are anticipated to fuel growth.
Because of its high prevalence of infectious diseases and increasing healthcare infrastructure, Asia Pacific is expected to see the highest CAGR during the projection period. For economic expansion, many diagnostic businesses focus on Asian nations like China and India. Some of the major drivers of the expansion of the regional Market in the Asia Pacific include the availability of a sizable base of target consumers and rising disposable income.
The global blood culture test market is segmented by product, method, and application.
Based on the product, the global blood culture test market is divided into consumables, instruments, software, and services.
Consumable is the most dominant in the global blood culture test market and is expected to grow at a CAGR of 10.6% during the forecast period. This dominance is due to increased laboratories using blood culture media, kits, reagents, and assays to diagnose to provide appropriate treatment. On the other hand, it is anticipated that the instruments segment will experience the highest growth rate throughout the forecast period. This is because there has been an increase in the demand for incubators, colony counters, and microscopes in hospitals and other diagnostic laboratories.
Based on the methodology, the global market for blood culture tests is divided into conventional and automated categories.
The conventional market segment holds the largest market share and is expected to grow at a CAGR of 9.2% during the forecast period. The simplest method of blood culture is conventional blood culture, which uses fluid culture bottles and a vacuum to produce results in two weeks. This method allows for the slow growth of microorganisms. This can be attributed to the widespread application of conventional blood culture tests in independent clinical laboratories and an increase in the use of conventional methods in hospital settings and pathology labs. However, it is anticipated that the automated segment will experience the highest market growth rate during the forecast period. This is due to manufacturers' increased investment in research and development for developing novel products and advancements in the technology used in healthcare to produce quick and accurate results.
Based on applications, the global market for blood culture tests is divided into bacteria, fungi, and others.
The bacterial segment leads the market since bacterial infection is one of the primary causes of bloodstream infection and sepsis, both potentially fatal conditions and expected to grow at a CAGR of 9.2% during the forecast period. Bacterial is the condition in which bacteria are present in the bloodstream and cause infections like urinary tract infections, sepsis, or kidney infections. On the other hand, due to an increase in the number of sepsis and bloodstream infection cases worldwide, it is anticipated that the fungal segment will experience the highest market growth rate during the forecast period. In addition, the growth of the fungal segment is helped along with increased healthcare awareness and the development of healthcare infrastructure.